Because local anesthetics are known to inhibit both sodium and potassium channels, and anesthetic properties have been attributed to the former effect, we compared their effects with those of tetrodotoxin (TTX), a selective Na + channel inhibitor with anesthetic activity, and 4-aminopyridine (4-AP), a selective potassium channel blocker with convulsive activity, on transmitter release during rest and in response to field (axonal) stimulation using the microvolume perfusion method and isolated prefrontal cortex and spinal cord slice preparations loaded with the radioactive transmitters
Introduction
Local anesthetics have been widely used in clinical practice for surgical anesthesia and for short-and long-term pain management, such as for treating postoperative and neuropathic pain (Berde and Strichartz, 2010) . During spinal and epidural anesthesia neurons in the dorsal horn are exposed to relatively high concentrations of local anesthetics that diffuse directly into the spinal cord (Bromage et al., 1963; Berde and Strichartz, 2010) and may cause adverse effects, such as convulsions (Agarwal et al., 1992) or cauda equina syndrome (Rigler et al., 1991) .
Although the incidence of adverse effects of local anesthetics has significantly diminished in recent decades (Faccenda and Finucane, 2001 ) and the permanent toxicity is very rare (0.01-0.07%) (Berde and Strichartz, 2010; Bouwman and Morre, 2013) , transient injuries do occur. The mechanisms by which local anesthetics exert adverse effects on the CNS are not well understood (Berde and Strichartz, 2010) .
It is generally accepted (van der Wal et al., 2015) that local anesthetics (e.g., lidocaine) have anesthetic, analgesic, antiinflammatory and antihyperalgesic properties mediated by their inhibitory effects on neuronal Na + (Scholz, 2002; Lenkey et al., 2011) , and K + (Wolff et al., 2014) also known that both Na + and K + channels are involved in transmitter release, no study has focused on the effects of local anesthetics on chemical neurotransmission in the CNS, the frontal cortex and the spinal cord. Therefore, we studied the release of dopamine and noradrenaline. Both are transmitters in the CNS and, similar to other transmitters (e.g., glutamate), are stored in vesicles and are released by axonal stimulation-evoked exocytosis in an external Ca 2+ concentration ([Ca 2+ ] o )-dependent manner; thus, they serve as an example of any type of transmitter. In addition, transmitters can also be released in a [Ca 2+ ] o -independent way under resting conditions, when the transmitter mainly released into the extraneuronal space results in high concentrations of catecholamines with long-lasting tonic effects on nonsynaptic receptors . Therefore, the present study was designed to determine the effects of lidocaine and bupivacaine on the resting and axonal stimulation-evoked release of 
Materials and methods

Animal experiments
We used Wistar (male) rats (120-150 g), and all of the studies were conducted in accordance with the principles outlined in the NIH Guidelines for the Care and Use of Laboratory Animals and were approved by the local Animal Care Committee at the Institute of Experimental Medicine, Budapest, Hungary.
Materials
All (Milusheva et al., 1996) and spinal cord (Nakai et al., 1999) slices was measured using the microvolume perfusion method (Milusheva et al., 1996) . The animals were sacrificed under slight (isoflurane) anesthesia, their brains were quickly removed, and the prefrontal cortex or spinal cord was dissected. Catecholaminergic terminals efficiently accumulate radiolabeled NA or DA due to the activities of transporters (Moron et al., 2002) located in the prefrontal cortex and spinal cord. Prefrontal cortex slices (400 m thick and 15.8 ± 0.52 mg in weight, n = 30) and spinal cord sections at the L6 to S1 level (400 m thick and 13.9 ± 2.9 mg in weight, n = 48) were prepared with a McIlwain tissue chopper from rats weighing 120-150 g. The slices were loaded with levo-[(7,8)-3 H]DA (60Ci/mmol and 3 Ci/ml; Amersham) or levo-[7-3 H]-NA (15Ci/mmol and 5 Ci/ml) for 45 min at 37 • C in Krebs solution containing 0.3 mM ascorbic acid and 0.03 mM Na 2 EDTA, and they were aerated with a 95% O 2 and 5% CO 2 gas mixture. After 45 min of loading, the tissues were transferred to an organ bath with a 0.5 ml capacity, and they were superfused with Krebs solution at a steady rate of 0.5 ml/min. The effluent was not collected for the first 60 min. Subsequently, fractions were collected every 3 min. The radioactivity remaining in the tissue was measured after perfusion (Milusheva et al., 1996) , and we calculated the amount (neuronal uptake) of radioactivity at the beginning of the experiments (the sum of radioactivity released during 19 collection periods and the radioactivity remaining after perfusion).
In the cerebral cortex samples, 75.2 ± 5.7% (the mean ± SEM of 30 observations) of the total radioactivity was accounted for DA, and 85.6 ± 4.1% (n = 18) was attributed to NA, as measured by high-pressure liquid chromatography combined with scintillation spectrometry. For the spinal cord slices 83.6 ± 5.8% (n = 16) of the radioactivity was released as NA. The remaining radioactivity was due to metabolites (Milusheva et al., 1996) , indicating that the radioactivity measured in the fractions can be safely attributed to labeled transmitter release into the perfusion fluid.
The level of radioactivity in the samples (by [ 3 H]DA or [ 3 H]NA and 3 H metabolites) was determined using a liquid scintillation counter (Packard 1900 Tri-Carb liquid scintillation spectrometer), and the counts were converted to absolute activity using external standards. The tritium release was expressed in Bq/g and as a percentage of the amount of radioactivity in the tissue at the time the release was measured (fractional release, FR%). FRR 1 and FRS 1 were taken as internal standards (controls) and are indicated in the figures. The release of tritium in response to the drug treatment or field (axonal) stimulation was compared with the basal release level and was expressed as the increase in the fractional release of tritium.
Nerve stimulation
A 2 Hz electrical field stimulation (supramaximal, 2 ms impulse duration) was used with a Grass S88 stimulator (Grass Medical Instrument, Quincy, MA, USA) through a pair of platinum ring electrodes. A total of 360 or 240 supramaximal shocks were delivered, as indicated.
Statistics
Statistical analysis of the data was performed with a two-tailed Student t-test and analysis of variance (ANOVA) with Dunnett's test. The results are presented as the mean ± SEM. The error bars in the figures represent the SEM and were only plotted when they exceeded the symbol size.
Results
Release of [ 3 H]DA from cerebral cortex slice preparations
In 30 experiments, the prefrontal cortex (PFC) slices contained 220.2 ± 9.5 kBq/g radioactivity following 45 min of loading with [ 3 H]DA and subsequent washing. Over a 3 min collection period at rest, the average release from the second resting samples of the PFC slices was 1.9 ± 0.1 kBq/g (1.00 ± 0.03% (n = 30) of the total radioactive content). The change in resting release over a 30 min period was always compared with the control value (FRR 1 ) determined during the 3 min collection period (FRR 2 /FRR 1 = 0.86 ± 0.05, n = 6).
In response to electrical field stimulation (2 Hz, 2 ms, and 360 shocks), the release was 14.0 ± 0.7 kBq/g (n = 30), which was 6.31 ± 0.23% of the radioactivity present in the PFC tissue at the time of stimulation. When the stimulation (FRS 1 = 5.83 ± 0.93%) was repeated 30 min after the first stimulation (S 2 ), the level of radioactivity released was 5.32 ± 1.33% (FRS 2 ), resulting in an FRS 2 /FRS 1 ratio of 1.04 ± 0.07 (n = 6, Fig. 1a) .
When voltage-dependent Na + influx (i.e., axonal conduction) was inhibited by the application of TTX (1 M) between the first and second stimulation, the evoked [ 3 H]DA release in response to field stimulation was significantly blocked with FRS 2 /FRS 1 = 0.12 ± 0.03 (Fig. 1b) . This finding indicates the neuronal origin of the released radioactivity. The resting release was not affected (FRR 2 /FRR 1 = 1.03 ± 0.008).
Epidural anesthetics are administered at concentrations of 1.5-2% (lidocaine, 55.2 mM; bupivacaine, 46.2 mM); anesthetics are administered at 1.5-5% for spinal anesthesia and at 1-2% for major nerve blocks. After epidural injection, the spread of the solution into the tissues of the epidural space is unpredictable (Hogan, 2002) , and neurons are then exposed to relatively high concentrations (e.g., 5-50 mM) of local anesthetics. Therefore, we administered anesthetics at concentrations ranging from 0.1 mM to 5 mM to test their effects on neurochemical transmission in the CNS. Lidocaine, at a concentration of 5 mM (Fig. 2c) , enhanced the resting release of [ 3 H]DA by more than six-fold, and 1.5 mM bupivacaine (Fig. 2d) increased the release by more than nine-fold. Note that the stimulation-evoked release was fully inhibited (Fig. 2) .
When CaCl 2 was removed and EGTA (1 mM), a Ca 2+ chelator, was added to the Krebs solution, 5 mM lidocaine enhanced the resting release of [ 3 H]DA (FRR 2 /FRR 1 = 5.94 ± 0.34 (n = 4)) (Fig. 3) to approximately the same extent as that observed in the normal solution (FRR 2 /FRR 1 = 6.84 ± 0.10) (Fig. 2c) . Under the control condition of the removal of Ca 2+ from the Krebs solution (1 mM EGTA was also added), the axonal stimulation failed to release [ 3 H]DA, but the resting release was not affected (data not shown).
4-AP significantly increased both the resting (FRR 2 /FRR 1 = 1.75 ± 0.13, p < 0.05) and axonal firing-associated (FRS 2 /FRS 1 = 2.52 ± 0.21, p < 0.01) [ 3 H]DA release ( Fig. 4a and b) . Our observations are in agreement with previous studies that have shown that 4-AP increases the release of dopamine in the brain (King et al., 2012) , the release of acetylcholine (Vizi et al., 1977) and noradrenaline in the heart (Sugimori et al., 1987) , and glutamate from synaptosomes (Tapia and Sitges, 1982) . Lidocaine was added to the Ca 2+ -free (CaCl2 was omitted and 1 mM EGTA was added) Krebs perfusion solution. The slices were stimulated (2 Hz, 360 shocks) once (S1 = 12.2 ± 0.6 kBq/g, FRS1 = 5.50 ± 0.44%, n = 6), as indicated. The asterisks indicate the level of significance, p < 0.01.
Release of [ 3 H]NA from cerebral cortex and spinal cord slice preparations
After the cerebral cortex slices were loaded with [ 3 H]NA, the average tissue uptake of radioactivity was 435.0 ± 69.8 kBq/g (n = 6). During the collection period (3 min), the fractional release of radioactivity was 0.89 ± 0.15% (1.9 ± 0.2 kBq/g) at rest. Axonal stimulation (S 1 ) led to the release of 10.9 ± 0.2 kBq/g of radioactivity (Fig. 5a ). The effect of lidocaine on the resting release depended on the concentration. The FRR 2 /FRR 1 values were 0.85 ± 0.02 (p > 0.05, n = 5), 1.87 ± 0.10 (p < 0.05, n = 5) and 2.53 ± 0.20 (p < 0.01, n = 6) at concentrations of 0.1, 1.5 and 3 mM, respectively. At a concentration of 3 mM, lidocaine significantly enhanced the resting release and reduced the stimulation-evoked release of [ 3 H]NA (Fig. 5b) .
In clinical practice, solutions of 0.5% lidocaine (18.4 mM) and bupivacaine (15.4 mM) that are locally injected into spinal space might result in relatively high local concentrations of these drugs. Therefore, we also studied the effect of lidocaine on [ 3 H]NA release from the spinal cord slices (Fig. 6a) . After 45 min of loading, the tissue contained 283.6 ± 50.4 kBq/g of radioactivity (n = 14). At rest, 0.7 ± 0.05% of the radioactive content was released during the 3 min collection period. Electrical field stimulation released [ 3 H]NA from the preparations (FRS 1 = 7.4 ± 0.9 kBq/g, n = 6) and the FRS 2 /FRS 1 was 0.91 ± 0.08 (n = 6). At a concentration of 5 mM, lidocaine enhanced the resting release and completely blocked the stimulation-evoked release (Fig. 6a) . 4-Aminopyridine (300 M) enhanced both the resting and stimulation-evoked release (Fig. 6b) .
Tetrodotoxin (1 M) fully inhibited the stimulation-evoked release (data not shown).
Discussion
We have shown that local anesthetics (lidocaine and bupivacaine) at concentrations > 0.5 mM produced a partial or complete dissociation of chemical neurotransmission, i.e., reduced or inhibited neuronal stimulation-evoked, [ To the best of our knowledge, our study is the first to provide neurochemical evidence that local anesthetics enhance transmitter release at rest (Fig. 2b-d) . The selective K + channel inhibitor 4-AP also enhanced the resting transmitter release, which is independent of the axonal activity and induces clonic and tonic seizures in patients (King et al., 2012) . However, while local anesthetics partially or fully inhibit it, 4-AP potentiates stimulation-evoked release from prefrontal cortex (Fig. 4) and spinal cord preparations (Fig. 6b) . Therefore, we suggest that the rare occurrence of adverse effects to local anesthetics is due to their effects on chemical transmission influenced by combined inhibitory effects on Na + and K + channels inhibiting the stimulation-evoked (an effect on Na + channels) and enhancing the resting release of catecholamines (an effect on K + channels). This conclusion is strongly supported by the findings that diazoxide, a K + channel opener reduces both the resting and stimulation-evoked release of noradrenaline (Takata et al., 1992; Oe et al., 1999) ; in addition, pinacidil, a drug with a similar effect on K + channels, has been shown to inhibit the stimulation-induced release of endogenous dopamine and noradrenaline (Soares-da-Silva and Fernandes, 1990) . Tetrodotoxin, a selective Na + channel blocker (Narahashi, 1972; Kohane et al., 1998) with local anesthetic activity (Padera et al., 2006) , fully inhibited the [Ca 2+ ] o -dependent release of transmitters evoked by axonal stimulation in both preparations. TTX is similar to local anesthetics in this respect, it is even able to potentiate the action of local anesthetics (Kohane et al., 1998; Padera et al., 2006) , but it failed to affect the [Ca 2+ ] o -independent release of [ 3 H]DA at rest and does not cause adverse CNS effects after systemic administration (Marcil et al., 2006) . TTX has no inhibitory effect on K + permeability.
Voltage-gated sodium channels are the pharmacological targets of a variety of drugs, such as analgesics, local anesthetics, antiarrhythmics and antiepileptics (Lenkey et al., 2010 (Lenkey et al., , 2011 . Presynaptic potassium channels play a key role in cellular physiology by regulating the efflux of K + ions and setting the resting membrane potential (Dodson and Forsythe, 2004; Kim and Kang, 2015) . It is known that local anesthetics are also able to inhibit K + channels (Scholz, 2002; Wolff et al., 2014) in neocortical 3 H]NA. S1 = 6.9 ± 0.9 kBq/g, S2 = 17.4 ± 2.5 (n = 4). (Andreasen and Hablitz, 1993) and dorsal horn (Olschewski et al., 1998) neurons. Since a variety of K + currents are known to be involved in the repolarization of the neuron action potential, any effect on K + channels may influence transmitter release.
It is notable that locally applied anesthetics (0.5-5% w/v, which is 15.4-154 mM for bupivacaine) that penetrate the tissue can easily result in local concentrations of >0.5 mM that are required to develop the local anesthetic effect (Schmidtmayer and Ulbricht, 1980) ; these concentrations are also sufficiently high to affect transmitter release, as observed in this study.
Subarachnoid injection of a local anesthetic (lidocaine, 75 mg) produces anesthesia lasting from 60 to 115 min (Moore et al., 1987) . It has been shown that the volume (42-81 ml) of lumbosacral cerebrospinal fluid is the primary determinant of sensory block extent and duration (Higuchi et al., 2004) . Accordingly, 75 mg of lidocaine administered into the lumbosacral cerebrospinal fluid (∼60 ml) might produce a 4-5 mM concentration, high enough to affect transmitter release. Continuous spinal anesthesia even with a relatively lower concentration that is increasingly administered over a long time period to treat postoperative neuropathic pain (Berde and Strichartz, 2010 ) also increases the chance of neurotoxicity.
It has been shown that dopaminergic (Cobacho et al., 2014 ) and noradrenergic (Takano and Yaksh, 1992) mechanisms are involved in the antiallodynic action of neuropathic pain; therefore, the release of NA in response to a spinal administration of local anesthetics is very likely involved in the pain-relief action. This conclusion is supported by the fact that the descending noradrenergic system originating from brainstem nuclei A5, A6 and A7 exerts analgesia by inhibiting glutamate release from the spinal nociceptive primary afferent fiber (Kamisaki et al., 1993) , which is an effect that can be blocked by ␣ 2 -adrenoceptor antagonists (Takano and Yaksh, 1992) . Indeed, clinically, intrathecal and epidural administration of ␣ 2 -adrenoceptor agonists (e.g., clonidine), drugs that are able to mimic the effect of NA with an agonist effect on these ␣ 2 -adrenoceptors, have been used for spinal analgesia for the treatment of intractable pain (Rauck et al., 1993) .
Local anesthetics increase the release of [ 3 H]NA or [ 3 H]DA at rest, resulting in a high ambient concentration of catecholamines and their toxic aldehyde metabolites (3,4-dihydroxyphenylacetaldehyde (DOPAL) and 3,4-dihydroxyphenylglycolaldehyde (DOPEGAL)) (Burke et al., 2004) ; these effects might also be involved in neurotoxic effects.
In clinical practice, an overdose, accidental rapid injection or local administration of a local anesthetic may produce adverse effects in the nervous system. An interesting problem that remains to be studied is how patients suffering from different somadendritic and axo-somatic channelopathies (Brager and Johnston, 2014) or being treated with noradrenaline uptake blockers may respond to local anesthetics. Nevertheless, although neurotoxicity from local anesthetics occurs very rarely, it may limit their clinical utility, and, at a minimum, caution should be exercised in selecting the volume, total dose and concentration of a specific anesthetic.
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